CORT financial statements
The full income statement, balance sheet, and cash-flow statement for Corcept Therapeutics Incorporated (CORT), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 761M YoY+12.8% | 675M YoY+39.9% | 482M YoY+20.0% | 402M YoY+9.8% | 366M YoY+3.4% | |
| Cost of revenue | 13.0M YoY+19.3% | 10.9M YoY+67.9% | 6.48M YoY+20.4% | 5.38M YoY+2.0% | 5.28M YoY-5.4% | |
| Research & development | 255M YoY+3.2% | 247M YoY+33.9% | 184M YoY+40.7% | 131M YoY+15.0% | 114M YoY-0.8% | |
| Selling, general & administrative | 449M YoY+60.1% | 280M YoY+52.1% | 184M YoY+20.6% | 153M YoY+24.9% | 122M YoY+16.2% | |
| Amortization of intangibles | — | — | 465K YoY-2.5% | 477K YoY+16.6% | 409K | |
| Operating income | 44.8M YoY-67.3% | 137M YoY+27.7% | 107M YoY-4.8% | 113M YoY-9.5% | 124M YoY-2.9% | |
| Other non-operating income | 21.7M YoY-11.7% | 24.5M YoY+42.1% | 17.3M YoY+385.7% | 3.56M YoY+572.4% | 529K | |
| Pre-tax income | 66.5M YoY-58.8% | 161M YoY+29.7% | 125M YoY+7.2% | 116M YoY-7.1% | 125M YoY-5.0% | |
| Income tax | -33.2M YoY-263.6% | 20.3M YoY+10.1% | 18.4M YoY+24.7% | 14.8M YoY+18.2% | 12.5M YoY-51.2% | |
99.7M YoY-29.4% | 141M YoY+33.0% | 106M YoY+4.7% | 101M YoY-9.9% | 113M YoY+6.1% | ||
$0.82 YoY-33.3% | $1.23 YoY+30.9% | $0.94 YoY+8.0% | $0.87 YoY-2.2% | $0.89 YoY+4.7% | ||
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
485M YoY+2.9% | 472M YoY+2.8% | 459M YoY-8.1% | 499M YoY+87.4% | 266M YoY-44.3% | ||
837M YoY-0.5% | 841M YoY+35.2% | 622M YoY+6.5% | 583M YoY+37.7% | 424M YoY-25.9% | ||
166M YoY+18.0% | 141M YoY+34.7% | 105M YoY+44.2% | 72.5M YoY+52.5% | 47.5M YoY+0.1% | ||
189M YoY+17.3% | 161M YoY+40.2% | 115M YoY+40.7% | 81.6M YoY+70.2% | 48.0M YoY-0.9% | ||
648M YoY-4.7% | 680M YoY+34.1% | 507M YoY+1.0% | 502M YoY+33.5% | 376M YoY-28.2% | ||
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
142M YoY-28.4% | 198M YoY+56.5% | 127M YoY+5.3% | 120M YoY-28.3% | 168M YoY+10.5% | ||
69.8M YoY+139.3% | -178M YoY-295.4% | 90.9M YoY+179.5% | -114M YoY-184.0% | 136M YoY+214.1% | ||
-220M YoY-677.3% | -28.3M YoY+80.9% | -149M YoY-760.5% | -17.3M YoY+94.3% | -303M YoY-2577.4% | ||
| FX effect on cash | 1.44M YoY+732.5% | -228K YoY-163.7% | 358K | — | — | |
| Net change in cash | -7.17M YoY+9.1% | -7.89M YoY-111.4% | 69.2M YoY+713.2% | -11.3M YoY-891.0% | 1.43M YoY-96.8% | |
| Income taxes paid | 13.0M YoY-78.5% | 60.3M YoY+26.6% | 47.6M YoY+19.8% | 39.7M YoY+336.6% | 9.10M YoY-16.1% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 3.70B YoY-30.4% | 5.32B YoY+58.8% | 3.35B YoY+53.1% | 2.19B YoY+4.2% | 2.10B YoY-31.6% | |
| P/E | 37.1× YoY-1.3% | 37.6× YoY+2.8% | 36.6× YoY+95.8% | 18.7× YoY+0.3% | 18.6× YoY-35.6% | |
| P/S | 4.9× YoY-38.3% | 7.9× YoY+5.9% | 7.4× YoY+35.3% | 5.5× YoY-4.1% | 5.7× YoY-33.9% | |
| P/B | 5.7× YoY-27.0% | 7.8× YoY+7.9% | 7.3× YoY+57.0% | 4.6× YoY-17.3% | 5.6× YoY-4.8% | |
| P/FCF | 26.1× YoY-3.7% | 27.1× YoY+25.0% | 21.7× YoY+34.8% | 16.1× YoY+28.4% | 12.5× YoY-38.5% | |
2.7% YoY+1.3% | 2.7% YoY-2.7% | 2.7% YoY-48.9% | 5.3% YoY-0.3% | 5.4% YoY+55.2% | ||
3.8% YoY+3.8% | 3.7% YoY-20.0% | 4.6% YoY-25.8% | 6.2% YoY-22.1% | 8.0% YoY+62.5% | ||
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: CORT's SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn't file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all CORT filings on SEC EDGAR → Not investment advice.
